Uğur Şahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)
September 18, 2023 09:25 AM EDT
Financing
R&D
Pharma

BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

Kyle LaHucik

Senior Reporter

Build­ing on its in­fec­tious dis­ease work in Covid-19, malar­ia and tu­ber­cu­lo­sis, BioN­Tech is now rolling out a Phase I/II test of a jab to pro­tect …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times